Compare Abeona Therapeutics Inc (ABEO) vs iShares Core High Dividend ETF (HDV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs iShares Core High Dividend ETF — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while iShares Core High Dividend ETF trades at $27.91. The key difference: iShares Core High Dividend ETF is trading nearer its 52-week high, Abeona Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | HDV | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | — |
52-Week High | $7.23 | $28.09 |
52-Week Low | $4.17 | $23.63 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
HDV trades at $27.70, down 1.21% on the day, with a bullish technical signal driven by moving averages and neutral oscillators. The ETF focuses on high-quality, high-dividend U.S. stocks, currently yielding around 3.0%, and has outperformed the S&P 500 over five years with lower volatility. Recent news highlights its defensive sector tilt toward healthcare and energy, though this introduces oil price sensitivity.
The outlook for HDV is favorable for income-focused investors seeking stable dividends and lower market correlation, but risks include sector concentration in energy and competitive pressure from lower-cost dividend ETFs. Long-term performance hinges on sustained dividend growth from its quality-focused portfolio amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →
